Tessera Therapeutics Stock
| Valuation | $1.7B1, 2 |
| Valuation Date | Apr 19, 2022 |
| Implied Valuation | n/a |
| Last Price | $2.50 |
| 52-Week High | $9.70 |
| 52-Week Low | $2.36 |
| YTD Return | -37.03% |
| 1-Year Return | -73.93% |
| 3-Year Return | n/a |
| Total Funding | $545M1, 3 |
| Latest Round Amount | $300M1 |
| Latest Round | Series C |
| Funding Rounds | 3 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Tessera Therapeutics
Tessera Therapeutics is a biotechnology company developing a genome engineering approach it calls Gene Writing. Its platform is designed to write therapeutic changes directly into a patient's DNA, from correcting single base pairs to inserting entire genes, using RNA-based Gene Writers delivered through non-viral lipid nanoparticles rather than by cutting the genome. The company targets genetic diseases such as sickle cell disease and alpha-1 antitrypsin deficiency, along with in vivo cell therapy applications. As a clinical-stage company it has no product revenue yet. It funds its work through venture financing, grants from governments and foundations, plus partnerships such as a 2025 collaboration with Regeneron to co-develop and commercialize its lead alpha-1 antitrypsin deficiency program.
Invest in Tessera Therapeutics
Tessera Therapeutics is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
News
Tessera Therapeutics Appoints Joseph Romanelli as President and CEO
Tessera named Joseph Romanelli president and CEO, succeeding Michael Severino, to lead the gene-writing company as it advances its clinical portfolio.
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
Tessera named Joseph Romanelli president and CEO, succeeding Michael Severino, as the company advances its first in vivo gene editing program into the clinic.
Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at ASGCT 29th Annual Meeting
Tessera presented preclinical data at the American Society of Gene and Cell Therapy meeting, reporting that a single dose of its Gene Writer edited about 85% of long-term hematopoietic stem cells in n...
Tessera Therapeutics Receives Gates Foundation Grant for HIV Cure Research
The Gates Foundation awarded Tessera a grant to support early-stage in vivo gene writing research aimed at developing scalable HIV cure approaches.
Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential HIV Cure
Tessera said it received a grant from the Gates Foundation to fund early-stage research into multiple Gene Writing strategies aimed at engineering immune cells in vivo toward a scalable cure for HIV.
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
The FDA granted Fast Track and Orphan Drug designations to TSRA-196, Tessera's lead in vivo gene editing program for alpha-1 antitrypsin deficiency, which is being developed with Regeneron.
Tessera Therapeutics Announces FDA Clearance of IND for TSRA-196
The FDA cleared Tessera's investigational new drug application for TSRA-196, its lead in vivo gene writing therapy for alpha-1 antitrypsin deficiency, enabling a Phase 1/2 trial.
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
Tessera said the FDA cleared its Investigational New Drug application for TSRA-196, allowing it to begin a first-in-human Phase 1/2 trial in adults with alpha-1 antitrypsin deficiency. The company als...
Gene editing startup Tessera to lay off 90 employees as it begins first clinical study
Tessera Therapeutics disclosed plans to cut 90 employees, about 35% of its workforce, in WARN notices, leaving roughly 160 staff as it narrows its focus around the Regeneron partnership and its first ...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop...
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
Tessera said it raised more than $300 million in Series C financing to build out its Gene Writing platforms and advance therapeutic programs, with investors including ADIA, Alaska Permanent Fund, Soft...